Remove 2023 Remove Heart Disease Remove Plaque
article thumbnail

Very high LDL no impact on plaque progression

Dr. Malcolm Kendrick

10th December 2023 A very important study – please watch Very high low density lipoprotein levels with no impact on plaque progression I interrupt my series on what is wrong with the health service to bring you breaking news. He states that five years is more than sufficient to detect any difference in plaque progression.

Plaque 144
article thumbnail

Why Waiting Until Age 50 To Address Risk Factors For Heart Disease Is Too Late.

Dr. Paddy Barrett

Subscribe now So why is it that so many people are having heart attacks at less than 65 years of age? The reason: They were accumulating plaque in their coronary arteries much earlier than their peers. You can’t have a heart attack if you don’t have plaque in your coronary arteries. The answer: Risk Factors.

article thumbnail

Results of CERTAIN Study Demonstrate Prominent Effects of Cleerly Products on Changing Clinical Management for Patients Suspected of Coronary Artery Disease

DAIC

Cleerly, a digital healthcare company focused on heart disease, has announced continued strong scientific evidence supporting the clinical utility of its products, detailing a study published online on Jan. 25, 2024 in the European Heart Journal Cardiovascular Imaging. With Plaque Features Associated with False Positives.

article thumbnail

Cleerly ISCHEMIA Software Device Billable With AMA Category I CPT Code for Noninvasive Estimates of Fractional Flow Reserve

DAIC

milla1cf Fri, 02/23/2024 - 11:54 February 23, 2024 — Cleerly , the company creating a new standard of care to aid in the diagnosis of heart disease, announced that its recently U.S. Sponsored by Cleerly and Presented at the American College of Cardiology Annual Scientific Meeting New Orleans LA 2023. 2023 Dec 12:jead339.

Ischemia 105
article thumbnail

Elixir Medical Granted FDA Breakthrough Device Designation for DynamX Bioadaptor

DAIC

The breakthrough designation, according to the Milpitas, CA-based technology company, is for an indication to improve coronary luminal diameter, restore hemodynamic modulation, and reduce plaque progression in patients with symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions. of the U.S.

article thumbnail

HeartFlow Achieves Landmark Milestone of 250,000 Patients Assessed for Coronary Artery Disease (CAD) with FFRCT Analysis

DAIC

Since its inception, HeartFlow has been committed to building a new standard of care for people at risk of heart disease. For over a decade, HeartFlow’s deep partnerships with more than 1,000 hospitals globally, including 80% of the top 50 heart hospitals in the U.S., REVEALPLAQUE Study, SCCT 2023. Data on file.

article thumbnail

Naturally Occurring Atherosclerosis Progression and In-Stent Restenosis: Exploring Histomorphological Associations Using Optical Coherence Tomography

Journal of Cardiovascular Pharmacology

This study enrolled 225 patients diagnosed with coronary heart disease and multivessel disease (MVD). A significantly higher proportion of patients in the ISR with non-target lesion progression (N-TLP) group exhibited lipid plaque formation compared to the ISR without N-TLP group (69.0% versus 39.8%, P < 0.001).